Clinical utility of lanreotide autogel® in gastroenteropancreatic neuroendocrine tumors

Rosa Maria Paragliola, Alfredo Pontecorvi, Salvatore Maria Corsello, Alessandro Prete, Giampaolo Papi, Francesco Torino, Andrea Corsello

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)

Abstract

Somatostatin analogs (SSAs), which were initially used to control hormonal syndromes associated with neuroendocrine neoplasms (NENs), have been successfully proposed as antiproliferative agents, able to control tumor growth in patients affected by gastroenteropancreatic (GEP)-NENs. The development of long-acting formulations of SSAs which require only weekly or monthly injections can improve patient compliance. In particular, lanreotide (LAN) Autogel ®, which is a viscous aqueous formulation supplied in ready-to-use prefilled syringes, can be administered every 28–56 days. Since its introduction in the clinical practice, several studies evaluated the clinical utility of LAN Autogel in the medical treatment of GEP-NENs. Although there is no evidence of an overall survival benefit, these studies confirm the efficacy of LAN Autogel in terms of benefit in progression-free survival, and in more than half of cases, a reduction of tumor markers can be observed during treatment with this drug. Moreover, LAN Autogel is widely recognized to be effective in controlling tumor-related symptoms in the majority of patients affected by GEP tumors, especially in patients affected by carcinoid syndrome, improving considerably patients’ quality of life.
Lingua originaleEnglish
pagine (da-a)3459-3470
Numero di pagine12
RivistaDrug Design, Development and Therapy
Volume10
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • 3003
  • Drug Discovery3003 Pharmaceutical Science
  • Gastroenteropancreatic neuroendocrine neoplasms
  • Gastroenteropancreatic neuroendocrine tumors
  • Lanreotide autogel
  • Pharmacology
  • Somatostatin analogs

Fingerprint Entra nei temi di ricerca di 'Clinical utility of lanreotide autogel® in gastroenteropancreatic neuroendocrine tumors'. Insieme formano una fingerprint unica.

Cita questo